SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 20, 2003
BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization) | 000-26727
(Commission
File Number) | 68-0397820
(IRS Employer
Identification No.) |
371 Bel Marin Keys Boulevard, Suite 210, Novato, California
(Address of principal executive offices) | | 94949
(Zip Code) |
| Registrant's telephone number, including area code: | (415) 884-6700 |
Not Applicable
(Former name or former address, if changed since last report)
===================================================================================================================
Item 5. Other Events.
On November 20, 2003, BioMarin Pharmaceutical Inc. (the “Registrant”), issued a press release regarding the Registrant’s plans to begin clinical trials with Phenoptin for the treatment of PKU and the Registrant’s co-development agreement with Merck Eprova AG, for the manufacturing and supply of Phenoptin. The Registrant’s press release issued on November 20, 2003 is attached hereto as Exhibit 99.1.
Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired.
Not Applicable.
(b) Pro Forma Financial Information.
Not Applicable.
(c) Exhibits.
Exhibit 99.1 Press Release of the Registrant dated November 20, 2003.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BioMarin Pharmaceutical Inc.,
a Delaware corporation |
| Date: November 20, 2003 | By: /s/ Louis Drapeau
Louis Drapeau
Chief Financial Officer |
EXHIBIT INDEX
Exhibit No. Description
Exhibit 99.1 Press Release of the Registrant dated November 20, 2003.
